Core Molding Technologies, Inc. (CMT)
AMEXMaterialsChemicals - SpecialtySnapshot 2026-09-04
$24.12+0.33%
Close 2026-09-04 · 1-day change
AMEXMaterialsChemicals - SpecialtySnapshot 2026-09-04
QuarterlyIQ Insights · CMT
Price, fair value, and the multiples that frame it on the same time axis. Scroll over the price chart to zoom.
Daily closes. Earnings/event dots inline.
A consensus fair price across 7 valuation methods, at three horizons. As of 2026-09-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $24 CMT trades at 28× p/e — 1.6× the 17× p/e peer median, and above its own 22× history. The market is re-rating it beyond its own range; our $20 fair value is medium-confidence here. Even valued only for durable growth at sustainable margins, it's worth about $33 — above today's price, so the premium reflects that growth case, not pure multiple expansion. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Score 100 = cheapest in the cohort, 0 = richest. Bars are filled left-to-right based on the peer-relative score (or PEG/self-history where shown).
Each method's implied share price per horizon. Provisional rows use a projected (historical-CAGR) growth input rather than analyst or management guidance.
| Method | Horizon | Est. price | Multiple | Per-share input | EPS source | Confidence |
|---|---|---|---|---|---|---|
| graham number | 12M | $18.92 | — | — | TTM | high |
| Peer EV/EBITDA | 12M | $32.45 | 10.0 | 3.10 | TTM | high |
| Peer P/E | 12M | $14.93 | 17.4 | 0.86 | TTM | high |
| Peer P/S | 12M | $42.33 | 1.4 | 29.21 | TTM | high |
| residual income |
A “consensus-then vs. actual-now” overlay is on the way — what our valuation estimate said on a past date versus where the price actually landed.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A long-thesis check that carries the widest uncertainty of the three horizons.
Above average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
No fragility gates fired. Regime (Mania) does not concentrate fragility.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Looks more expensive than peers.
Richer than its own typical valuation.
Trailing four: 2025-Q3, 2025-Q4, 2026-Q1, 2026-Q2
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
| 12M |
| $16.58 |
| — |
| — |
| TTM |
| high |
| Own P/E history | 12M | $18.53 | 21.5 | 0.86 | TTM | high |
| triangulated | 12M | $15.31 | 17.4 | 0.88 | Triangulated | high |
| Peer P/E | 3Y | $37.81 | 17.4 | 2.18 | Hist. CAGR(prov.) | medium |
| Peer P/S | 3Y | $54.97 | 1.4 | 37.94 | guidance | medium |
| Own P/E history | 3Y | $46.93 | 21.5 | 2.18 | Hist. CAGR(prov.) | medium |
| Peer P/E | 5Y | $41.68 | 17.4 | 2.40 | Hist. CAGR(prov.) | high |
| Peer P/S | 5Y | $60.61 | 1.4 | 41.83 | guidance | high |
| Own P/E history | 5Y | $51.75 | 21.5 | 2.40 | Hist. CAGR(prov.) | high |